Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CTSV | O60911 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376396 | 1.00 | PDE3B (0.40) | PDE3BPDE3AKDM4EMAPK1ALDH1A1 | |
| SCHEMBL4375766 | 0.96 | PDE3B (0.39) | PDE3BPDE3AKDM4EMAPK1ALDH1A1 | |
| SCHEMBL4377096 | 0.95 | KDM4E (0.38) | PDE3BPDE3AKDM4EMAPK1ALDH1A1 | |
| SCHEMBL4297391 | 0.88 | PRKAB2 (0.42) | PDE3BPDE3AKDM4EMAPK1ALDH1A1 | |
| SCHEMBL2002754 | 0.87 | KDM4E (0.46) | PDE3BPDE3AKDM4EMAPK1ALDH1A1 | |
| SCHEMBL1806456 | 0.85 | PDE3B (0.47) | PDE3BPDE3AKDM4EMAPK1ALDH1A1 | |
| SCHEMBL5495216 | 0.84 | KDM4E (0.41) | KDM4EMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1507501 | 0.83 | PDE3B (0.43) | PDE3BPDE3AKDM4EMAPK1ALDH1A1 | |
| SCHEMBL263796 | 0.83 | EGFR (0.39) | KDM4EMAPK1ALDH1A1 | |
| SCHEMBL4373778 | 0.81 | EHMT2 (0.52) | KDM4EALDH1A1HPGDKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | claimed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | claimed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | claimed |
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| EP-2155656-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | Cipla Limited (IN) | 2010-02-24 | — | — | EP | disclosed |
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008125867-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | CIPLA LIMITED (IN) | 2008-10-23 | — | — | WO | disclosed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137586-A1 | Process for the Preparation of Gefitinib | EGFR, BRAF, KRAS | PDE3B 1795/4885PDE3A 2218/4885KDM4E 1987/4885 |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | NQO2, SDHA, CYP3A4 | PDE3B 3161/4885PDE3A 2770/4885KDM4E 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.